Skip to content

MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction)

Safety and Preliminary Efficacy Study of Intravenous Administration of MiSaver® (Myocardial Infarction Saver) After Acute Myocardial Infarction, a Phase I/IIa Clinical Trial.

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04050163
Acronym
MiSaver®
Enrollment
11
Registered
2019-08-08
Start date
2021-01-26
Completion date
2023-05-04
Last updated
2024-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

Heart Attack

Brief summary

The objective of the present study is to establish the safety and efficacy of MiSaver® Stem Cell Treatment After a Heart Attack (Acute Myocardial Infarction)

Interventions

BIOLOGICALMiSaver®

Intravenous administration of MiSaver® Stem Cell via peripheral vein access.

Sponsors

Chung Shan Medical University
CollaboratorOTHER
Honya Medical Inc
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Single/participant blinded

Intervention model description

Sequential dose escalating

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 20\ 80 * Acute Myocardial Infarction 1 to 10 days * Cardiac enzyme CK-MB or Troponin \> 2X of high-end normal value * ST-elevation on EKG (STEMI) * Presence of regional wall motion abnormality * Left ventricular ejection fraction (LVEF) of ≤40% * Hemodynamically stable past 24 hour * Participants with adequate pulmonary function * Peripheral artery oxygen saturation ≥97% * Karnofsky performance status scores of ≥60.

Exclusion criteria

* Age \<20 or \>80 * Pregnant or breast feeding * Positive adventitious infections (such as HIV, hepatitis ) * Revascularization via coronary artery bypass surgery is required * Coronary revascularization procedures is anticipated during the 6-month study period * Severe aortic or mitral valve narrowing * Evidence of life-threatening arrhythmia on baseline electrocardiogram (ECG) * Short of breath unable to receive PCI examination or treatment * Malignant tumor * Hematopoietic dysplasia * Severe organ disease * With less than 1 year of life expectancy * Chronic kidney disease with CCr\<20ml/min * Kidney disease on renal dialysis

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Treatment Emergent Adverse Events12 monthsNumber of Adverse Events

Secondary

MeasureTime frameDescription
Left ventricle stroke volume12 monthsEchocardiogram assessment on left ventricle stroke volume (volume of blood pumped from the left ventricle per beat (ml).
End diastolic volume12 monthsEchocardiogram assessment on volume of blood in the left ventricle at the end of diastolic filling (cc)
Left ventricular ejection fraction (LVEF)12 monthsCalculated by dividing the volume of blood pumped from the left ventricle per beat (stroke volume) by the volume of blood collected in the left ventricle at the end of diastolic filling (end-diastolic volume).
Participants Functional Activity by NYHA Classification12 monthsThe New York Heart Association (NYHA) Functional Classification is a useful tool for classifying the extent of functional limitations in patients with heart conditions. The system categorizes patients into one of four categories based on the level of limitation they experience during physical activity, with symptoms ranging from mild shortness of breath or angina to more severe breathing difficulties. The NYHA classification focuses specifically on limitations related to physical activity and provides a straightforward approach to assessing a patient's condition. By using this system, healthcare providers can quickly and easily determine the level of functional limitation in their patients and tailor treatment plans accordingly.
Participants Functional Activity by CCS Classification12 monthsThe Canadian Cardiovascular Society grading of angina pectoris, also known as the CCS Functional Classification, is a widely used clinical tool that classifies the severity of exertional angina. It allows doctors to assess the degree of angina severity in patients, and subsequently develop a tailored treatment plan. Although there are no definitive therapy guidelines specific to each class, healthcare providers can use the CCS grading system as a framework to guide treatment planning based on the severity of angina and other individual factors such as age and the risk of major cardiac complications. By utilizing the CCS grading system, healthcare providers can ensure that patients receive personalized treatment that addresses their unique needs and circumstances.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026